Abstract
Cytosolic 5′-nucleotidase II (NT5C2) is involved in the development of 1-β-d-arabinofuranosylcytosine (ara-C) resistance and has been associated with clinical outcome in patients receiving ara-C-based chemotherapy. NT5C2 inactivates ara-C by dephosphorylating ara-C monophosphate to ara-C. In this study, we sequenced NT5C2 in genomic DNA samples from International HapMap project panels with European [Centre d'Etude du Polymorphisme Humain (CEU); n = 90] or African [Yoruba people in Ibadan, Nigeria (YRI); n = 90] ancestry. We identified 41 genetic variants [one insertion-deletion and 40 single nucleotide polymorphisms (SNPs)], including three nonsynonymous SNPs (Y3A, K47R, and Q136R). Twenty-five SNPs were novel and 16 overlapped with the HapMap data. Subjects with African ancestry had NT5C2 mRNA expression levels that was significantly higher than those with European ancestry (p = 0.005). Furthermore, there was a correlation between NT5C2 mRNA expression and ara-C sensitivity in CEU but not in YRI cell lines. None of the nonsynonymous SNPs demonstrated any effect on NT5C2 activity. The genotypes of several SNPs were significantly associated with NT5C2 mRNA expression and/or ara-C sensitivity in CEU cell lines, but very few were significant in YRI cell lines. Of most interest, SNPs (linkage disequilibrium group CEU.12) in the 5′-untranslated region were associated with NT5C2 expression and ara-C sensitivity in HapMap cell lines and with NT5C2 mRNA expression and ara-C sensitivity in diagnostic leukemic blasts from pediatric patients with acute myeloid leukemia. Functional genomics analysis demonstrated that the promoter SNP rs11191612 was associated with altered luciferase activation in reporter assays and altered DNA-protein binding in gel shift assays. These results suggest that genetic variations in NT5C2 influence its expression and, potentially, cellular responses to nucleoside analogs.
Footnotes
This study was supported by National Institutes of Health National Cancer Institute [Grant R01-CA132946] (to J.K.L.); and the American Lebanese Syrian Associated Charities.
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
doi:10.1124/jpet.111.182873.
↵ The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material.
-
ABBREVIATIONS:
- ara-C
- 1-β-d-arabinofuranosyl-cytosine (cytarabine)
- AML
- acute myeloid leukemia
- ara-CTP
- ara-C triphosphate
- ara-CMP
- ara-C monophosphate
- NT5C
- cytoplasmic 5′ nucleotidase
- 5′UTR
- 5′-untranslated region
- SNP
- single nucleotide polymorphism
- PCR
- polymerase chain reaction
- CEU
- Centre d'Etude du Polymorphisme Humain
- YRI
- Yoruba people in Ibadan, Nigeria
- AUC
- area under the survival curve
- UTR
- untranslated region
- BMGC
- Biomedical Genomics Center
- WT
- wild type
- EMSA
- electrophoretic mobility shift assays
- mt
- mutant
- MSP
- methylation-specific polymerase chain reaction
- EFS
- event free survival
- OS
- overall survival
- MRD
- minimal residual disease
- MTT
- 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide
- LD
- linkage disequilibrium.
- Received April 19, 2011.
- Accepted June 13, 2011.
- Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|